SSRIs, Not Buspirone, Are the Recommended First-Line Medication for This 12-Year-Old with GAD
Despite the patient's request for buspirone, an SSRI should be offered as the first-line pharmacologic treatment for this 12-year-old female with generalized anxiety disorder. 1
Why SSRIs Over Buspirone
The 2020 AACAP guidelines explicitly recommend SSRIs as the medication class to consider for patients 6-18 years old with GAD, based on moderate strength of evidence demonstrating improvement in anxiety symptoms, global function, treatment response, and disorder remission 1. In contrast, buspirone failed to separate from placebo in two large randomized controlled trials specifically conducted in pediatric patients with GAD 2. These abandoned trials included 568 children and adolescents aged 6-17 years, and buspirone showed no significant benefit over placebo on primary anxiety measures in either the fixed-dose or flexible-dose study 2.
The Evidence Against Buspirone in Pediatric GAD
- The FDA label for buspirone indicates it is approved for adult GAD management, with efficacy demonstrated only in adult outpatients 3
- Pediatric trials were underpowered but showed no signal of efficacy even at therapeutic doses 2
- Drop-out rates due to adverse events were significantly higher with buspirone versus placebo in pediatric patients (p=0.011) 2
- Buspirone may be particularly ineffective in patients with prior benzodiazepine exposure, as it is not cross-tolerant with benzodiazepines 4
Recommended SSRI Options
Start with one of these SSRIs that had sufficient data in the AACAP review:
- Sertraline (may require twice-daily dosing at low doses)
- Fluoxetine (longest half-life, permits once-daily dosing)
- Fluvoxamine
- Paroxetine (though associated with higher suicidality risk and discontinuation syndrome compared to other SSRIs) 1
SSRI Dosing Strategy
Begin with a subtherapeutic "test" dose to assess tolerability, as initial anxiety/agitation can occur 1. Then:
- Increase in smallest available increments at 1-2 week intervals for shorter half-life SSRIs (sertraline, citalopram)
- Increase at 3-4 week intervals for longer half-life SSRIs (fluoxetine)
- Expect clinically significant improvement by week 6 and maximal improvement by week 12 or later 1
Critical Safety Monitoring
All SSRIs carry a black box warning for suicidal thinking and behavior through age 24 years 1. The pooled absolute risk is 1% for antidepressants versus 0.2% for placebo (NNH=143), but close monitoring is essential, especially in the first months and after dose adjustments 1.
Common adverse effects include: dry mouth, nausea, diarrhea, headache, insomnia, appetite changes, and weight changes. Potentially serious effects include behavioral activation, hypomania, sexual dysfunction, seizures, abnormal bleeding, and serotonin syndrome 1.
Optimal Treatment Approach
Consider combination treatment (CBT + SSRI) preferentially over medication alone 1. The Child-Adolescent Anxiety Multimodal Study demonstrated that combination CBT plus sertraline improved anxiety, global function, treatment response, and remission rates compared to either treatment alone (moderate strength of evidence) 1.
Addressing the Buspirone Request
When discussing the patient's request for buspirone:
- Acknowledge the request and explain that buspirone is FDA-approved only for adults with GAD 3
- Present the pediatric trial data showing lack of efficacy in children and adolescents with GAD 2
- Explain that SSRIs have the strongest evidence base for pediatric GAD with demonstrated improvements in morbidity and quality of life 1
- Emphasize that parental oversight of medication regimens is paramount 1
If SSRIs Fail or Are Not Tolerated
SNRIs represent a second-line option, with duloxetine being the only SNRI with FDA approval for GAD in children ≥7 years old 1. However, SNRIs require blood pressure and pulse monitoring due to risk of sustained hypertension 1.